Akebia secures up to $140M Symbiotic Capital term loan, repays $55M BlackRock facility
Akebia Therapeutics announced a senior secured term loan with Symbiotic Capital, closed November 12, 2026 and disclosed November 16, 2026. A $60 million initial tranche was funded and used to repay its $55 million BlackRock loan in full, and up to $80 million more may be provided at the lender's discretion. The loan matures in 60 months at a variable rate of at least 11.5%, and the company reaffirmed cash runway guidance of at least two years.
16 Nov 2026 · Akebia Therapeutics, Inc. AKBA · Company news
Company's press release (SEC filing): Akebia Therapeutics, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
More FinancingAll →
Financing
Kyntra Bio halts FG-3246 prostate cancer work, cuts royalty-financing cap and plans roxadustat MDS Phase 3
16 Nov 2026 · Kyntra Bio, Inc. KYNB · Company news
Financing
NervGen Pharma reports C$80.1M cash at Q3 2026 after May public offering; nine-month net income of C$2.5M
16 Nov 2026 · Nervgen Pharma Corp. NGEN · Company news
Financing
Windward Bio closes $251.2M IPO and private placement, with underwriters' option exercised in full
16 Nov 2026 · Windward Bio Group AG · Company news
Financing
Hydrofarm posts Q3 2026 sales drop to $14.5M and wipes out $109M term loan in October recapitalization
16 Nov 2026 · Hydrofarm Holdings Group, Inc. HYFM · Company news
Financing
AMC Robotics posts Q3 2026 net loss of $2.02M on lower revenue and one-time financing costs
16 Nov 2026 · AMC Robotics Corp AMCI · Company news
Financing
Grande Group signs $40M ordinary share purchase facility with White Lion Capital
16 Nov 2026 · Grande Group Ltd/HK GRAN · Company news